Harmony Biosciences (HRMY) Competitors $36.67 +1.20 (+3.38%) Closing price 04:00 PM EasternExtended Trading$36.78 +0.10 (+0.29%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HRMY vs. ROIV, GRFS, LEGN, RVMD, RYTM, RNA, NUVL, ABVX, AXSM, and CRSPShould you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), Abivax (ABVX), Axsome Therapeutics (AXSM), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Harmony Biosciences vs. Its Competitors Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Abivax Axsome Therapeutics CRISPR Therapeutics Harmony Biosciences (NASDAQ:HRMY) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations. Does the media favor HRMY or ROIV? In the previous week, Harmony Biosciences had 15 more articles in the media than Roivant Sciences. MarketBeat recorded 25 mentions for Harmony Biosciences and 10 mentions for Roivant Sciences. Harmony Biosciences' average media sentiment score of 0.29 beat Roivant Sciences' score of -0.08 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Roivant Sciences 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more volatility and risk, HRMY or ROIV? Harmony Biosciences has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Do institutionals and insiders have more ownership in HRMY or ROIV? 86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 23.6% of Harmony Biosciences shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate HRMY or ROIV? Harmony Biosciences presently has a consensus price target of $51.00, indicating a potential upside of 39.08%. Roivant Sciences has a consensus price target of $16.50, indicating a potential upside of 37.97%. Given Harmony Biosciences' higher probable upside, analysts clearly believe Harmony Biosciences is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harmony Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25 Is HRMY or ROIV more profitable? Harmony Biosciences has a net margin of 23.44% compared to Roivant Sciences' net margin of -2,111.79%. Harmony Biosciences' return on equity of 26.34% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Harmony Biosciences23.44% 26.34% 17.71% Roivant Sciences -2,111.79%-15.90%-14.95% Which has stronger earnings and valuation, HRMY or ROIV? Harmony Biosciences has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarmony Biosciences$714.73M2.95$145.49M$3.1011.83Roivant Sciences$29.05M279.86-$171.98M-$0.25-47.84 SummaryHarmony Biosciences beats Roivant Sciences on 13 of the 17 factors compared between the two stocks. Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRMY vs. The Competition Export to ExcelMetricHarmony BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.04B$3.04B$5.55B$9.83BDividend YieldN/A2.27%4.62%4.11%P/E Ratio11.837.7521.9425.46Price / Sales2.95360.34460.58105.19Price / Cash12.0442.0537.7558.93Price / Book2.737.638.476.06Net Income$145.49M-$54.65M$3.26B$265.11M7 Day Performance5.77%3.95%3.56%2.90%1 Month Performance7.85%11.46%5.97%3.99%1 Year Performance4.50%13.04%42.70%26.92% Harmony Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRMYHarmony Biosciences4.6834 of 5 stars$36.67+3.4%$51.00+39.1%+6.2%$2.04B$714.73M11.83200Analyst RevisionROIVRoivant Sciences2.0991 of 5 stars$11.17-2.8%$16.50+47.7%+3.5%$7.81B$29.05M0.00860News CoverageGap DownGRFSGrifols3.9807 of 5 stars$10.60-0.6%$10.30-2.8%+47.6%$7.33B$7.81B9.0623,822Positive NewsLEGNLegend Biotech3.7438 of 5 stars$36.24-2.1%$73.33+102.4%-34.2%$6.80B$627.24M0.002,609Trending NewsEarnings ReportAnalyst ForecastRVMDRevolution Medicines3.9684 of 5 stars$34.70-0.9%$68.82+98.3%-18.0%$6.54B$11.58M0.00250News CoverageEarnings ReportAnalyst RevisionRYTMRhythm Pharmaceuticals3.5717 of 5 stars$94.31+2.5%$101.57+7.7%+116.9%$6.11B$130.13M0.00140News CoveragePositive NewsAnalyst RevisionRNAAvidity Biosciences2.6299 of 5 stars$45.75-1.2%$67.00+46.4%+3.9%$5.96B$10.90M-15.25190Upcoming EarningsAnalyst RevisionNUVLNuvalent2.9361 of 5 stars$74.95+1.1%$119.60+59.6%+6.2%$5.32BN/A-15.3040Earnings ReportUpcoming EarningsAnalyst RevisionABVXAbivax3.8711 of 5 stars$69.00-1.6%$92.33+33.8%+554.3%$5.30BN/A0.0061AXSMAxsome Therapeutics4.8383 of 5 stars$103.96-0.8%$178.00+71.2%+23.9%$5.23B$385.69M-20.50380CRSPCRISPR Therapeutics2.9004 of 5 stars$55.41+0.7%$71.60+29.2%+20.7%$5.00B$37.31M-10.20460Analyst Revision Related Companies and Tools Related Companies Roivant Sciences Alternatives Grifols Alternatives Legend Biotech Alternatives Revolution Medicines Alternatives Rhythm Pharmaceuticals Alternatives Avidity Biosciences Alternatives Nuvalent Alternatives Abivax Alternatives Axsome Therapeutics Alternatives CRISPR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRMY) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access